Genetic profiles and clinical features in subcutaneous panniculitis-like T-cell lymphomas.

HAVCR2 mutation germline mutation hematology lymphoma subcutaneous panniculitis‐like T‐cell lymphoma

Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
17 Sep 2024
Historique:
revised: 27 08 2024
received: 30 04 2024
accepted: 02 09 2024
medline: 18 9 2024
pubmed: 18 9 2024
entrez: 17 9 2024
Statut: aheadofprint

Résumé

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare peripheral T-cell lymphoma characterized by cutaneous lesions and immunologic manifestations. The five-year survival rate of SPTCL has been reported to be over 80%, indicating a favorable prognosis. Recent studies have uncovered recurrent germline variants in HAVCR2, encoding an immunomodulator. In this study, we integrated whole-exome sequencing data from 60 samples collected from 36 SPTCL patients, encompassing six patients of our cohort and 30 patients of publicly available data. We identified 138 somatic mutations in skin tumors of 24 patients and HAVCR2 germline mutations in 23 of 29 patients. HAVCR2 p.Tyr82Cys mutations were identified in four of six Japanese patients. During the clinical courses of four patients, cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone were administered to all patients, but it resulted in incomplete responses in all four patients. However, disease conditions of all patients remained stable with additional treatment, including autologous peripheral blood stem cell transplantation. Over a 7.5-year median follow-up, one patient developed autoimmune-related diseases, while one developed other hematological malignancy, resulting in death. To our knowledge, this is the first report of recurrent HAVCR2 germline mutations in Japanese patients, suggesting the necessity for long-term follow-up.

Identifiants

pubmed: 39288772
doi: 10.1111/cas.16345
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Japan Society for the Promotion of Science
ID : JP20J20851
Organisme : Japan Society for the Promotion of Science
ID : JP21K16261
Organisme : Japan Society for the Promotion of Science
ID : JP23K15293
Organisme : Japan Society for the Promotion of Science
ID : JP23K15316
Organisme : Japan Society for the Promotion of Science
ID : JP23K15317

Informations de copyright

© 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Fujii K, Hamada T, Shimauchi T, et al. Cutaneous lymphoma in Japan, 2012–2017: a nationwide study. J Dermatol Sci. 2020;97(3):187‐193. doi:10.1016/j.jdermsci.2020.01.010
Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis‐like T‐cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;111(2):838‐845. doi:10.1182/blood-2007-04-087288
López‐Lerma I, Peñate Y, Gallardo F, et al. Subcutaneous panniculitis‐like T‐cell lymphoma: clinical features, therapeutic approach, and outcome in a case series of 16 patients. J Am Acad Dermatol. 2018;79(5):892‐898. doi:10.1016/j.jaad.2018.05.1243
Koh J, Jang I, Mun S, et al. Genetic profiles of subcutaneous panniculitis‐like T‐cell lymphoma and clinicopathological impact of HAVCR2 mutations. Blood Adv. 2021;5(20):3919‐3930. doi:10.1182/bloodadvances.2021004562
Michonneau D, Petrella T, Ortonne N, et al. Subcutaneous panniculitis‐like T‐cell lymphoma: immunosuppressive drugs induce better response than Polychemotherapy. Acta Derm Venereol. 2017;97(3):358‐364. doi:10.2340/00015555-2543
Buyse S, Teixeira L, Galicier L, et al. Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med. 2010;36(10):1695‐1702. doi:10.1007/s00134-010-1936-z
Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21(5):245‐253. doi:10.1016/j.blre.2007.05.001
Gayden T, Sepulveda FE, Khuong‐Quang DA, et al. Germline HAVCR2 mutations altering TIM‐3 characterize subcutaneous panniculitis‐like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nat Genet. 2018;50(12):1650‐1657. doi:10.1038/s41588-018-0251-4
Polprasert C, Takeuchi Y, Kakiuchi N, et al. Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis‐like T‐cell lymphoma. Blood Adv. 2019;3(4):588‐595. doi:10.1182/bloodadvances.2018028340
Sonigo G, Battistella M, Beylot‐Barry M, et al. HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis‐like T‐cell lymphoma. Blood. 2020;135:1058‐1061. doi:10.1182/blood.2019003811
Li Z, Lu L, Zhou Z, et al. Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis‐like T‐cell lymphoma. Br J Haematol. 2018;181(3):406‐410. doi:10.1111/bjh.14611
Germline HAVCR2 mutations altering TIM‐3 characterize subcutaneous panniculitis‐like T‐cell lymphomas with hemophagocytic lymphohistiocytic syndrome – EGA European Genome‐Phenome Archive. Accessed February 5, 2024. https://ega‐archive.org/studies/EGAS00001002765
Paired whole exome sequence of subcutaneous panniculitis‐like T‐cell lymphoma – EGA European Genome‐Phenome Archive. Accessed February 5, 2024. https://ega‐archive.org/studies/EGAS00001003282
GenomonPipeline. 2023. Accessed February 5, 2024. https://github.com/Genomon‐Project
Gudmundsson S, Singer‐Berk M, Watts NA, et al. Variant interpretation using population databases: lessons from gnomAD. Hum Mutat. 2022;43(8):1012‐1030. doi:10.1002/humu.24309
Robinson JT, Thorvaldsdottir H, Turner D, Mesirov JP. igv.js: an embeddable JavaScript implementation of the integrative genomics viewer (IGV). Bioinformatics. 2023;39(1):btac830. doi:10.1093/bioinformatics/btac830
International Non‐Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non‐Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987‐994. doi:10.1056/NEJM199309303291402
Gallamini A, Stelitano C, Calvi R, et al. Peripheral T‐cell lymphoma unspecified (PTCL‐U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474‐2479. doi:10.1182/blood-2003-09-3080
Henter JI, Horne A, Aricó M, et al. HLH‐2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124‐131. doi:10.1002/pbc.21039
Stuver R, Epstein‐Peterson ZD, Horwitz SM. Few and far between: clinical management of rare extranodal subtypes of mature T‐cell and NK‐cell lymphomas. Haematologica. 2023;108(12):3244‐3260. doi:10.3324/haematol.2023.282717

Auteurs

Yui Okamura (Y)

School of Medicine and Health Sciences, College of Medicine, University of Tsukuba, Tsukuba, Japan.

Kenichi Makishima (K)

Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.

Yasuhito Suehara (Y)

Department of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Sakurako Suma (S)

Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.

Yoshiaki Abe (Y)

Department of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Ryota Matsuoka (R)

Department of Pathology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Tatsuhiro Sakamoto (T)

Department of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Keiichiro Hattori (K)

Department of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Yasuhisa Yokoyama (Y)

Department of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Takayasu Kato (T)

Department of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Department of Clinical Laboratory, University of Tsukuba Hospital, Tsukuba, Japan.

Toru Nanmoku (T)

Department of Clinical Laboratory, University of Tsukuba Hospital, Tsukuba, Japan.

Takeshi Iwasaki (T)

Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Kenichi Nishiyama (K)

Department of Pathology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.

Koji Kato (K)

Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Yasuhide Takeuchi (Y)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.

Hideki Makishima (H)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Naoya Nakamura (N)

Department of Pathology, Tokai University School of Medicine, Isehara, Japan.

Shigeru Chiba (S)

Department of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Mamiko Sakata-Yanagimoto (M)

Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Department of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Division of Advanced Hemato-Oncology, Transborder Medical Research Center, University of Tsukuba, Tsukuba, Japan.

Classifications MeSH